Back to Search Start Over

Pathological mitophagy disrupts mitochondrial homeostasis in Leber's hereditary optic neuropathy.

Authors :
Danese A
Patergnani S
Maresca A
Peron C
Raimondi A
Caporali L
Marchi S
La Morgia C
Del Dotto V
Zanna C
Iannielli A
Segnali A
Di Meo I
Cavaliere A
Lebiedzinska-Arciszewska M
Wieckowski MR
Martinuzzi A
Moraes-Filho MN
Salomao SR
Berezovsky A
Belfort R Jr
Buser C
Ross-Cisneros FN
Sadun AA
Tacchetti C
Broccoli V
Giorgi C
Tiranti V
Carelli V
Pinton P
Source :
Cell reports [Cell Rep] 2022 Jul 19; Vol. 40 (3), pp. 111124.
Publication Year :
2022

Abstract

Leber's hereditary optic neuropathy (LHON), a disease associated with a mitochondrial DNA mutation, is characterized by blindness due to degeneration of retinal ganglion cells (RGCs) and their axons, which form the optic nerve. We show that a sustained pathological autophagy and compartment-specific mitophagy activity affects LHON patient-derived cells and cybrids, as well as induced pluripotent-stem-cell-derived neurons. This is variably counterbalanced by compensatory mitobiogenesis. The aberrant quality control disrupts mitochondrial homeostasis as reflected by defective bioenergetics and excessive reactive oxygen species production, a stress phenotype that ultimately challenges cell viability by increasing the rate of apoptosis. We counteract this pathological mechanism by using autophagy regulators (clozapine and chloroquine) and redox modulators (idebenone), as well as genetically activating mitochondrial biogenesis (PGC1-α overexpression). This study substantially advances our understanding of LHON pathophysiology, providing an integrated paradigm for pathogenesis of mitochondrial diseases and druggable targets for therapy.<br />Competing Interests: Declaration of interests V.C. and C.L.M. are both involved in clinical trials with idebenone (Santhera Pharmaceuticals) in LHON patients; V.C., C.L.M., and A.A.S. are involved in gene therapy trials with Lumevoq (GenSight Biologics) in LHON patients. V.C. and A.A.S. also serve as consultants in the advisory board of Chiesi Farmaceutici.<br /> (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
2211-1247
Volume :
40
Issue :
3
Database :
MEDLINE
Journal :
Cell reports
Publication Type :
Academic Journal
Accession number :
35858578
Full Text :
https://doi.org/10.1016/j.celrep.2022.111124